Amphetamine abuse
diseaseOn this page
Summary
Amphetamine abuse (MONDO:0003969) is a disease and 4 clinical trials. Top therapeutic interventions include dexfenfluramine, fenfluramine, and citicoline. A subtype of substance abuse — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Clinical trials: 4
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | amphetamine abuse |
| Mondo ID | MONDO:0003969 |
| MeSH | D019969 |
| DOID | DOID:670 |
| ICD-11 | 879494155 |
| SNOMED CT | 84758004 |
| UMLS | C0236807 |
| MedGen | 66744 |
| Is cancer (heuristic) | no |
Disease family
This is a subtype of substance abuse. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by developmental or physiological process › psychiatric disorder › substance-related disorder › substance abuse › amphetamine abuse
Related subtypes (7): opioid abuse, antidepressant type abuse, hallucinogen abuse, alcohol abuse, cocaine abuse, barbiturate abuse, phencyclidine abuse
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 4.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 4 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT06960265 | Not specified | NOT_YET_RECRUITING | Effects of Repetitive Transcranial Magnetic Stimulations in Patients With Amphetamine Use Disorders |
| NCT00377299 | Not specified | COMPLETED | A Pilot Study of Citicoline add-on Therapy in Patients With Bipolar Disorder or Major Depressive Disorder and Amphetamine Abuse or Dependence |
| NCT01273701 | Not specified | UNKNOWN | Combination of Psychosocial Intervention and Slow Prosecutions for the Treatment of Methamphetamine Abuse/Dependence |
| NCT01296802 | Not specified | COMPLETED | Investigation of Serotonin Neurotransmission in MDMA Users Using Combinated Dexfenfluramine Challenge and PET Imaging |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| DEXFENFLURAMINE | 4 | 3 |
| FENFLURAMINE | 4 | 1 |
| CITICOLINE | 3 | 2 |
Related Atlas pages
- Drugs: Dexfenfluramine, Fenfluramine, Citicoline